MHC Class II molecules are integral to the adaptive immune response, serving as specialised antigen-presenting proteins on the surface of professional antigen-presenting cells. They bind peptide ...

创新多组学队列研究学术论坛近日，西北大学研究团队在期刊《Advanced Science》上发表了研究论文，题为“O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune ...

Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer. This is an ASCO Meeting ...

CHARLESTON, S.C., April 13, 2026--(BUSINESS WIRE)--Leukogene Therapeutics, Inc., an early‑stage oncology company developing MHC class II-engager immunotherapies for immunologically cold cancers, today ...

CHARLESTON, S.C.--(BUSINESS WIRE)--#AML--Leukogene Therapeutics, Inc., an early‑stage oncology company developing MHC class II-engager immunotherapies for immunologically cold cancers, today announced ...

Clinical utilization of precision oncology decision support for genomically-informed cancer therapy. PD-1, PD-L1, and B7-H3 expression in Human Immunodeficiency Virus (HIV) infected patients with ...